🔒 Incyte wins FDA approval for Niktimvo, considers future
September 5, 2024
Niktimvo is approved for treatment of chronic graft-versus-host disease. Incyte and its partner developer forecast that it may earn $650 million in net profit.
chat_bubble0 Comment
visibility136 Views
Premier Digital Partners
© 2024 Delaware Business Times
